Protocol Adaptations
The COVID-19 pandemic required multiple protocol adaptations. All study activity paused from March 9, 2020 through June 25, 2020. Pulmonary function testing was unavailable from March 2020 into late 2021 because of infection-control measur…
1 sources - 5 claims
The COVID-19 pandemic required multiple protocol adaptations. All study activity paused from March 9, 2020 through June 25, 2020. Pulmonary function testing was unavailable from March 2020 into late 2021 because of infection-control measures. National Jewish Health was added as a study site in September 2021. The protocol removed type 2 biomarker requirements for stable biologic and de novo biologic groups after tezepelumab approval.